Cancer Patients Cumulatively Saved Around Rs 294 Crore Due To Price Control: JP Nadda

New Delhi: The government makes all efforts to ensure affordable and accessible treatment is available for cancer patients amid a rise in cases in India, Health Minister JP Nadda said on Friday.

Replying to supplementary questions during Question Hour in the Lok Sabha, Nadda said the government made all efforts to ensure that affordable and accessible treatment was available to the patients.

“The number of cancer cases is going up, it is increasing by almost 2.5 per cent every year,” Nadda said.

In men, cases of oral and lung cancer are on the up while more women are getting breast cancer, he added.

More than 1.55 million cancer cases are being registered every year, Nadda said.

“There is a list of 131 essential cancer medicines, which are in Schedule 1, (that) are monitored and (their) pricing is decided by the government. These are the commonly used medicines,” Nadda said.

He said patients cumulatively saved around Rs 294 crore due to this price control.

“There are 28 combinations, which are not in this list but the NPPA (National Pharmaceutical Pricing Authority) and the government have controlled their pricing as well,” he said.

“We have tried to make cancer drugs affordable,” he added.

Responding to another question on healthcare infrastructure, Nadda said the government was apprised of the matter and expansion of medical colleges were happening so that there could be more doctors.

“There should be a balance in quality and quantity of medical education. We are trying to go as fast as we can but, at the same time, (we) do not want to compromise on the quality of medical doctors,” he said.

Nadda informed the House that the number of medical colleges had gone up from 387 in 2014 to 731 at present while the number of MBBS seats rose from 51,348 seats to 1,12,112 (1.12 lakh) during the same period.

The number of postgraduate seats for medical students has gone up from 31,185 in 2014 to 72,627 at present, he added.

Related Posts

  • Pharma
  • July 16, 2025
  • 126 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 40 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.